References

Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system

10.1080/08830185.2021.1954638 · 2022 · External reference

Gut dysbiosis in oncology: a risk factor for immunoresistance

10.1038/s41422-025-01212-6 · 2026 · External reference

A comprehensive review of immune checkpoint inhibitors for cancer treatment

10.1016/j.intimp.2024.113365 · 2024 · External reference

CAR T therapy beyond cancer: the evolution of a living drug

10.1038/s41586-023-06243-w · 2023 · External reference

Role and mechanism of gut microbiota in human disease

10.3389/fcimb.2021.625913 · 2021 · External reference

Gut microbiota, leaky gut, and autoimmune diseases

10.3389/fimmu.2022.946248 · 2022 · External reference

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

10.1016/s1470-2045(18)30261-4 · 2018 · External reference

The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants

10.1016/j.chom.2020.12.001 · 2021 · External reference

Microbial metabolites and their influence on the tumor microenvironment

10.3389/fimmu.2025.1675677 · 2025 · External reference

Secondary bile acids as immune and metabolic mediators

10.1016/j.it.2025.12.008 · 2026 · External reference

Gut-liver axis, microbiota, bile acids, and immune response in pathogenesis of primary sclerosing cholangitis: an overview

10.3390/jcm14217817 · 2025 · External reference

Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer

10.1038/s41586-022-05435-0 · 2022 · External reference

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

10.1126/science.aan4236 · 2018 · External reference

Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity

10.1016/j.immuni.2022.01.006 · 2022 · External reference

Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy

10.1097/cm9.0000000000003687 · 2025 · External reference

The chimeric antigen receptor detection toolkit

10.3389/fimmu.2020.01770 · 2020 · External reference

Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification

10.1080/19490976.2025.2486519 · 2025 · External reference

Programming CAR-T cells to kill cancer

10.1038/s41551-018-0235-9 · 2018 · External reference

Immunotherapy resistance in solid tumors: mechanisms and potential solutions

10.1080/15384047.2024.2315655 · 2024 · External reference

Immune checkpoint inhibitors: basics and challenges

10.2174/0929867324666170804143706 · 2019 · External reference

Green roof development knowledge map: a review of visual analysis using CiteSpace and VOSviewer

10.1016/j.heliyon.2024.e24958 · 2024 · External reference

Critical role of the gut microbiota in immune responses and cancer immunotherapy

10.1186/s13045-024-01541-w · 2024 · External reference

Microbiome-modulated immunotherapy in oncology: current applications and future prospects

10.1016/j.semcancer.2026.01.001 · 2026 · External reference

Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy

10.3389/fimmu.2025.1710880 · 2025 · External reference

Short-chain fatty acids: linking diet, the microbiome and immunity

10.1038/s41577-024-01014-8 · 2024 · External reference

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

10.1126/science.aao3290 · 2018 · External reference

Gut-liver axis: barriers and functional circuits

10.1038/s41575-023-00771-6 · 2023 · External reference

Role of gut microbial metabolites in the pathogenesis of primary liver cancers

10.3390/nu16142372 · 2024 · External reference

The Ah receptor from toxicity to therapeutics: Report from the 5th AHR meeting at Penn State University, USA, June 2022

10.3390/ijms24065550 · 2023 · External reference

Cancer immune evasion, immunoediting and intratumour heterogeneity

10.1038/s41577-024-01111-8 · 2025 · External reference

Gut microbiota, metabolites and host immunity

10.1038/nri.2016.42 · 2016 · External reference

Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer

10.1038/s41467-024-54565-8 · 2024 · External reference

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

10.1126/science.aan3706 · 2018 · External reference

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

10.1126/science.aaz7015 · 2021 · External reference

Gut-liver axis: pathophysiological concepts and clinical implications

10.1016/j.cmet.2022.09.017 · 2022 · External reference

Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies

10.3389/fimmu.2025.1638352 · 2025 · External reference

Resistance mechanisms to anti-PD cancer immunotherapy

10.1146/annurev-immunol-070621-030155 · 2022 · External reference

Chimeric antigen receptor T-cell therapy for solid tumors

10.1016/j.hoc.2023.05.009 · 2023 · External reference

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis

10.1016/j.xcrm.2021.100383 · 2021 · External reference

CAR-macrophage therapy alleviates myocardial ischemia-reperfusion injury

10.1161/circresaha.124.325212 · 2024 · External reference

A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction

10.3389/fimmu.2024.1493250 · 2024 · External reference

Short-chain fatty acids in the tumor microenvironment: from molecular mechanisms to cancer therapy

10.7150/thno.119304 · 2026 · External reference

CAR-NK cells: a promising cellular immunotherapy for cancer

10.1016/j.ebiom.2020.102975 · 2020 · External reference

Intratumoral microbiota: implications for cancer progression and treatment

10.3389/fmicb.2025.1551515 · 2025 · External reference

Gut microbiota-immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities

10.3389/or.2025.1687901 · 2025 · External reference

Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy

10.1038/s41571-023-00789-4 · 2023 · External reference

Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy

10.1038/s41392-022-01304-4 · 2023 · External reference

Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC

10.1038/s41522-025-00785-9 · 2025 · External reference

Immunotherapy: a promising approach for glioma treatment

10.3389/fimmu.2023.1255611 · 2023 · External reference

Intratumoral microbiota and metabolites: dual roles in cancer progression and therapeutic opportunities

10.1186/s12964-025-02623-z · 2026 · External reference

Gut microbiota in cancer immune response and immunotherapy

10.1016/j.trecan.2021.01.010 · 2021 · External reference

Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell

10.1080/19490976.2023.2249143 · 2023 · External reference